Joseph K Belanoff

Summary

Publications

  1. ncbi request reprint Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone
    Joseph K Belanoff
    Corcept Therapeutics, Inc, Menlo Park, CA 94025, USA
    J Mol Neurosci 19:201-6. 2002
  2. doi request reprint Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men
    Coleman Gross
    Corcept Therapeutics Incorporated, Menlo Park, California, USA
    Obesity (Silver Spring) 18:2295-300. 2010
  3. doi request reprint Mifepristone treatment of olanzapine-induced weight gain in healthy men
    Coleman Gross
    Corcept Therapeutics, Menlo Park, CA 94025, USA
    Adv Ther 26:959-69. 2009
  4. doi request reprint Efficacy and safety of mifepristone for the treatment of psychotic depression
    Christine M Blasey
    Corcept Therapeutics Incorporated, Menlo Park, CA, USA
    J Clin Psychopharmacol 31:436-40. 2011
  5. doi request reprint A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction
    Christine M Blasey
    Corcept Therapeutics, 149 Commonwealth Drive, Menlo Park, CA 94025, United States
    Contemp Clin Trials 30:284-8. 2009
  6. ncbi request reprint 2-Benzenesulfonyl-8a-benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists
    Robin D Clark
    Corcept Therapeutics, 149 Commonwealth Avenue, Menlo Park, CA 94025, USA
    Bioorg Med Chem Lett 17:5704-8. 2007
  7. ncbi request reprint An open label trial of C-1073 (mifepristone) for psychotic major depression
    Joseph K Belanoff
    Corcept Therapeutics Inc, Menlo Park, California 94025, USA
    Biol Psychiatry 52:386-92. 2002
  8. ncbi request reprint The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats
    Katherine L Beebe
    Corcept Therapeutics, Menlo Park, CA 94205, USA
    Behav Brain Res 171:225-9. 2006
  9. ncbi request reprint Discovery and optimization of novel, non-steroidal glucocorticoid receptor modulators
    Nicholas C Ray
    Argenta Discovery Ltd, 8 9 Spire Green Centre, Flex Meadow, Harlow, Essex, UK
    Bioorg Med Chem Lett 17:4901-5. 2007

Detail Information

Publications9

  1. ncbi request reprint Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone
    Joseph K Belanoff
    Corcept Therapeutics, Inc, Menlo Park, CA 94025, USA
    J Mol Neurosci 19:201-6. 2002
    ..Additionally, this study test the hypothesis that AD subjects with elevated cortisol at baseline will perform more poorly on neuropsychological exams that do subjects with low cortisol...
  2. doi request reprint Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men
    Coleman Gross
    Corcept Therapeutics Incorporated, Menlo Park, California, USA
    Obesity (Silver Spring) 18:2295-300. 2010
    ..Future research should continue to test the potential of glucocorticoid antagonists to alleviate the deleterious side effects associated with use of antipsychotic medications...
  3. doi request reprint Mifepristone treatment of olanzapine-induced weight gain in healthy men
    Coleman Gross
    Corcept Therapeutics, Menlo Park, CA 94025, USA
    Adv Ther 26:959-69. 2009
    ..The objective of this study was to determine if mifepristone, a glucocorticoid receptor antagonist, could prevent olanzapine-induced weight gain...
  4. doi request reprint Efficacy and safety of mifepristone for the treatment of psychotic depression
    Christine M Blasey
    Corcept Therapeutics Incorporated, Menlo Park, CA, USA
    J Clin Psychopharmacol 31:436-40. 2011
    ....
  5. doi request reprint A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction
    Christine M Blasey
    Corcept Therapeutics, 149 Commonwealth Drive, Menlo Park, CA 94025, United States
    Contemp Clin Trials 30:284-8. 2009
    ....
  6. ncbi request reprint 2-Benzenesulfonyl-8a-benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists
    Robin D Clark
    Corcept Therapeutics, 149 Commonwealth Avenue, Menlo Park, CA 94025, USA
    Bioorg Med Chem Lett 17:5704-8. 2007
    ..These compounds were devoid of affinity for other steroidal receptors (ER, AR, MR, and PR). Analogues based on an alternative putative binding mode (CP-like) were found to be inactive...
  7. ncbi request reprint An open label trial of C-1073 (mifepristone) for psychotic major depression
    Joseph K Belanoff
    Corcept Therapeutics Inc, Menlo Park, California 94025, USA
    Biol Psychiatry 52:386-92. 2002
    ..The rationale for treating patients with psychotic major depression (PMD) with glucocorticosteroid receptor (GR) antagonists is explained...
  8. ncbi request reprint The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats
    Katherine L Beebe
    Corcept Therapeutics, Menlo Park, CA 94205, USA
    Behav Brain Res 171:225-9. 2006
    ..0002). Results suggest that mifepristone, a potent glucocorticoid antagonist, may both reduce and prevent olanzapine-induced weight gain in rats...
  9. ncbi request reprint Discovery and optimization of novel, non-steroidal glucocorticoid receptor modulators
    Nicholas C Ray
    Argenta Discovery Ltd, 8 9 Spire Green Centre, Flex Meadow, Harlow, Essex, UK
    Bioorg Med Chem Lett 17:4901-5. 2007
    ..Optimization of the initial hit to provide potent compounds which exhibit good selectivity against other steroidal nuclear hormone receptors is described...